MétaCan
Menu
Back to cohort
Record W2790856692 · doi:10.1016/j.mayocp.2017.11.002

The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women

2018· review· en· W2790856692 on OpenAlexfundno aff
Anita H. Clayton, Irwin Goldstein, Noel N. Kim, Stanley E. Althof, Stephanie S. Faubion, Brooke Faught, Sharon J. Parish, James A. Simon, Linda Vignozzi, Kristin Christiansen, Susan R. Davis, Murray A. Freedman, Sheryl A. Kingsberg, Paraskevi‐Sofia Kirana, Lisa Larkin, Marita P. McCabe, Richard Sadovsky

Bibliographic record

VenueMayo Clinic Proceedings · 2018
Typereview
Languageen
FieldMedicine
TopicSexual function and dysfunction studies
Canadian institutionsnot available
FundersAstellas PharmaNovo NordiskEisaiRoivant SciencesPerrigo Company Charitable FoundationCovis PharmaRegeneron PharmaceuticalsAscend TherapeuticsMillendo TherapeuticsValeant Pharmaceuticals InternationalBayer HealthCareSanofiAmgenPfizerAllerganShionogiSage TherapeuticsGlaxoSmithKlineJanssen PharmaceuticalsRadius HealthNew England Research InstitutesAstellas Pharma US
KeywordsHypoactive sexual desire disorderMedicineSexual desireReproductive healthBiopsychosocial modelPsychiatryClinical psychologyHuman sexualityPopulation

Abstract

fetched live from OpenAlex

The International Society for the Study of Women's Sexual Health process of care (POC) for management of hypoactive sexual desire disorder (HSDD) algorithm was developed to provide evidence-based guidelines for diagnosis and treatment of HSDD in women by health care professionals. Affecting 10% of adult females, HSDD is associated with negative emotional and psychological states and medical conditions including depression. The algorithm was developed using a modified Delphi method to reach consensus among the 17 international panelists representing multiple disciplines. The POC starts with the health care professional asking about sexual concerns, focusing on issues related to low sexual desire/interest. Diagnosis includes distinguishing between generalized acquired HSDD and other forms of low sexual interest. Biopsychosocial assessment of potentially modifiable factors facilitates initiation of treatment with education, modification of potentially modifiable factors, and, if needed, additional therapeutic intervention: sex therapy, central nervous system agents, and hormonal therapy, guided in part by menopausal status. Sex therapy includes behavior therapy, cognitive behavior therapy, and mindfulness. The only central nervous system agent currently approved by the US Food and Drug Administration (FDA) for HSDD is flibanserin in premenopausal women; use of flibanserin in postmenopausal women with HSDD is supported by data but is not FDA approved. Hormonal therapy includes off-label use of testosterone in postmenopausal women with HSDD, which is supported by data but not FDA approved. The POC incorporates monitoring the progress of therapy. In conclusion, the International Society for the Study of Women's Sexual Health POC for the management of women with HSDD provides a rational, evidence-based guideline for health care professionals to manage patients with appropriate assessments and individualized treatments.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.057
metaresearch head score (Gemma)0.087
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.057
Threshold uncertainty score0.299

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0570.087
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.004
Bibliometrics0.0050.006
Science and technology studies0.0020.001
Scholarly communication0.0040.002
Open science0.0020.005
Research integrity0.0020.005
Insufficient payload (model declined to judge)0.0070.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.113
GPT teacher head0.428
Teacher spread0.315 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations221
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueMayo Clinic ProceedingsSame topicSexual function and dysfunction studiesFrench-language works237,207